EFG Capital International’s Legend Biotech LEGN Stock Holding History

EFG Capital International’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$472K	Buy	+6,834	New	+$447K	0.11%	109

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EFG Capital International's LEGN Position: Q2 2023 in Review

EFG Capital International opened a new position in Legend Biotech (LEGN) in Q2 2023: 6,834 shares worth $472K. The stake represents 0.11% of the portfolio and ranks #109 among its holdings.

194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

EFG Capital International held 6,834 shares of Legend Biotech worth $472K as of Q2 2023.
Legend Biotech was a new EFG Capital International position in Q2 2023.
Legend Biotech made up 0.11% of EFG Capital International's portfolio in Q2 2023, its #109 holding.
194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.